Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in advanced solid tumors
NCT06342336Phase 1Recruiting
- Sponsor
- Qingdao Sino-Cell Biomedicine Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-IT101 in solid tumor, sponsored by Qingdao Sino-Cell Biomedicine Co., Ltd. Primary endpoints: Adverse Events (AE) at 12 months and Serious Adverse Events (SAE) at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
HS-IT101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06342336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342336.